Predictors of mortality and morbidity in patients with chronic heart failure.

AIMS We aimed to develop prognostic models for patients with chronic heart failure (CHF). METHODS AND RESULTS We evaluated data from 7599 patients in the CHARM programme with CHF with and without left ventricular systolic dysfunction. Multi-variable Cox regression models were developed using baseline candidate variables to predict all-cause mortality (n=1831 deaths) and the composite of cardiovascular (CV) death and heart failure (HF) hospitalization (n=2460 patients with events). Final models included 21 predictor variables for CV death/HF hospitalization and for death. The three most powerful predictors were older age (beginning >60 years), diabetes, and lower left ventricular ejection fraction (EF) (beginning <45%). Other independent predictors that increased risk included higher NYHA class, cardiomegaly, prior HF hospitalization, male sex, lower body mass index, and lower diastolic blood pressure. The model accurately stratified actual 2-year mortality from 2.5 to 44% for the lowest to highest deciles of predicted risk. CONCLUSION In a large contemporary CHF population, including patients with preserved and decreased left ventricular systolic function, routine clinical variables can discriminate risk regardless of EF. Diabetes was found to be a surprisingly strong independent predictor. These models can stratify risk and help define how patient characteristics relate to clinical course.

[1]  M. Domanski,et al.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. , 2003, Journal of the American College of Cardiology.

[2]  J. Jones,et al.  Nonsteroidal anti-inflammatory drug-associated dyspepsia: basic mechanisms and future research. , 2001, The American journal of medicine.

[3]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[4]  S. Fisher,et al.  QRS duration and mortality in patients with congestive heart failure. , 2002, American heart journal.

[5]  B. Pitt,et al.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. , 1989, Journal of the American College of Cardiology.

[6]  M. Drazner,et al.  Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. , 2001, Journal of the American College of Cardiology.

[7]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[8]  F. Harrell,et al.  Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.

[9]  S. Yusuf,et al.  Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. , 2001, Journal of the American College of Cardiology.

[10]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[11]  R. Califf,et al.  Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. , 2000, The American journal of cardiology.

[12]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[13]  R M Lang,et al.  The Relationship Between Cardiothoracic Ratio and Left Ventricular Ejection Fraction in Congestive Heart Failure , 1998 .

[14]  Salim Yusuf,et al.  A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. , 2004, The American journal of medicine.

[15]  R. Prescott,et al.  A prognostic index to predict long‐term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors , 2003, European journal of heart failure.

[16]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[17]  A. Hoes,et al.  Predicting mortality in patients with heart failure: a pragmatic approach , 2003, Heart.

[18]  Eric J. Eichhorn Prognosis determination in heart failure. , 2001, The American journal of medicine.

[19]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[20]  P. Varadarajan,et al.  Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. , 2003, Journal of cardiac failure.

[21]  M. Lauer,et al.  Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. , 2003, Journal of the American College of Cardiology.

[22]  C. Yancy,et al.  Gender differences in advanced heart failure: insights from the BEST study. , 2003, Journal of the American College of Cardiology.

[23]  A. Hoes,et al.  Classification of heart failure in population based research: An assessment of six heart failure scores , 1997, European Journal of Epidemiology.

[24]  G. Onder,et al.  Body mass index and mortality among hospitalized patients. , 2000, Archives of internal medicine.

[25]  M. Drazner,et al.  Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. , 2004, American heart journal.

[26]  Peter C. Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.